PLRZHealthcare · Biotechnology

PLRZ Stock Forecast: Polyrizon Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$11

+1.91% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$21.5M

Ticker Nerd rank

14 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−2.6%

−20.8%

YTD

+25.9%

+26.1%

From 52W high

−37.7%

From 52W low

+241.3%

$17

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

PLRZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Polyrizon Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Momentum

Growth

Quality

Revisions

Issuance

Volatility

Accruals

Value

Size (88): Smaller than most of the companies we track.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLRZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLRZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLRZ appears on the weeks it earns a place.

Estimates

PLRZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Polyrizon Ltd. (PLRZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: —
Price / book: 0.8×
EV / EBITDA: −0.8×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −25.4%
Return on assets: −28.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PLRZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
PLRZPolyrizon Ltd.	$21.5M	14
NEUPNeuphoria Therapeutics, Inc.	$21.0M	7
COCPCocrystal Pharma, Inc.	$22.2M	56
ABVCABVC BioPharma, Inc.	$22.6M	14
CELUCelularity, Inc.	$22.7M	18
ALLRAllarity Therapeutics, Inc.	$22.8M	30
MRKRMarker Therapeutics, Inc.	$23.2M	59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Polyrizon Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLRZ news & analysis

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

GlobeNewsWire · 20 Aug 2026positive

Polyrizon announced it has completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker (PL-14) study and is advancing toward enrollment of 120 patients. The company is a development-stage biotech specializing in intranasal hydrogels.

Why it matters — Completing the clinical site network moves Polyrizon closer to patient enrollment in its NASARIX™ study, a key development milestone for the company's pipeline.

FAQ

Frequently asked questions about PLRZ stock

How does Ticker Nerd's model rank PLRZ?

As at 22 Aug 2026, Polyrizon Ltd. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

What is the PLRZ stock forecast for 2030?

No analyst covering Polyrizon Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRZ are extrapolating price history, which says nothing about the business.

How has PLRZ stock performed over the past year?

Polyrizon Ltd. returned +26.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Polyrizon Ltd. do?

What is the latest news on PLRZ?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment". Polyrizon announced it has completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker (PL-14) study and is advancing toward enrollment of 120 patients. The company is a development-stage biotech specializing in intranasal hydrogels.

Company

About Polyrizon Ltd.

Polyrizon Ltd is a clinical development stage biotechnology company focused on innovative nasal hydrogel technologies for respiratory health and protective applications. The company develops medical device hydrogels delivered as nasal sprays that form a thin, bioadhesive barrier in the nasal cavity, designed to act as a “biological mask” against a broad range of airborne viruses, allergens, and other environmental particles. Its core Capture and Contain platform uses naturally occurring building blocks to create a shield that helps limit contact between inhaled agents and nasal epithelial tissue. In parallel, Polyrizon Ltd is advancing its Trap and Target technology, aimed at intranasal delivery of active pharmaceutical ingredients for potential therapeutic use. Operating today from its headquarters in Raanana, Israel, and founded in 2005, the company occupies a niche at the intersection of medical devices and drug delivery systems, serving healthcare markets that seek non-systemic, preventive, and supportive nasal solutions for infectious disease exposure and allergy management.

CEO Mr. Tomer Izraeli · 2 employees · Israel · https://www.polyrizon-biotech.com